| 34.13 0.03 (0.09%) | 01-29 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 40.95 | 1-year : | 47.82 |
| Resists | First : | 35.06 | Second : | 40.95 |
| Pivot price | 33.81  |
|||
| Supports | First : | 32.98 | Second : | 31.7 |
| MAs | MA(5) : | 34.36 |
MA(20) : | 33.56 |
| MA(100) : | 32.67 |
MA(250) : | 29.82 |
|
| MACD | MACD : | 0.5 |
Signal : | 0.5 |
| %K %D | K(14,3) : | 73.7 |
D(3) : | 81 |
| RSI | RSI(14): 60.5 |
|||
| 52-week | High : | 37.77 | Low : | 22.36 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ GLPG ] has closed below upper band by 35.9%. Bollinger Bands are 30.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 34.38 - 34.54 | 34.54 - 34.69 |
| Low: | 33.53 - 33.72 | 33.72 - 33.9 |
| Close: | 33.82 - 34.12 | 34.12 - 34.39 |
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis. In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Tue, 27 Jan 2026
Galapagos NV (GLPG) Stock Analysis: Navigating The Upside Amidst Biotech Volatility - DirectorsTalk Interviews
Thu, 22 Jan 2026
(GLPG) Risk Channels and Responsive Allocation - Stock Traders Daily
Mon, 05 Jan 2026
Galapagos Stock Rises After Hours On Starting To Wind Down Cell Therapy Activities, Subsequent Workforce Reduction - Stocktwits
Mon, 05 Jan 2026
Galapagos to Wind Down Global Cell Therapy Operations and Close Five Sites - TipRanks
Mon, 05 Jan 2026
Galapagos (GLPG) to Cease Cell Therapy Operations - GuruFocus
Mon, 22 Dec 2025
Galapagos: Pivoting From Clinical Risk To Strategic Capital Allocation (NASDAQ:GLPG) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 66 (M) |
| Shares Float | 45 (M) |
| Held by Insiders | 25.3 (%) |
| Held by Institutions | 22.8 (%) |
| Shares Short | 988 (K) |
| Shares Short P.Month | 1,040 (K) |
| EPS | -7.83 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 43.11 |
| Profit Margin | -152 % |
| Operating Margin | -58.6 % |
| Return on Assets (ttm) | -5.2 % |
| Return on Equity (ttm) | -16.8 % |
| Qtrly Rev. Growth | 18.8 % |
| Gross Profit (p.s.) | -3.15 |
| Sales Per Share | 4.35 |
| EBITDA (p.s.) | -4.21 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -269 (M) |
| Levered Free Cash Flow | -30 (M) |
| PE Ratio | -4.37 |
| PEG Ratio | 0 |
| Price to Book value | 0.79 |
| Price to Sales | 7.83 |
| Price to Cash Flow | -8.36 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|